Ranibizumab Does Not Worsen Retinal Degeneration in Intermediate AMD, Study Finds
A post hoc analysis of the PREVENT trial suggests quarterly ranibizumab did not appear to affect drusen volume, drusen area, or GA progression compared to sham.
Source: hcplive.com